Here's a statement of the obvious: The opinions expressed here are those of the participants, not those of the Mutual Fund Observer. We cannot vouch for the accuracy or appropriateness of any of it, though we do encourage civility and good humor.
This has impact far beyond the price of the stock. We may look back on today as a watershed moment:
"This is the first time an investigational drug for Alzheimer's disease has demonstrated a statistically significant reduction on amyloid plaque as well as a statistically significant slowing of clinical impairment in patients with prodromal or mild disease."
@Scott: noted your interest in getting back into HQL. Tekla announced authorization to repurchase up to 12% of outstanding shares. I guess that will benefit me, but it's hard to call the shares undervalued.
@Scott: noted your interest in getting back into HQL. Tekla announced authorization to repurchase up to 12% of outstanding shares. I guess that will benefit me, but it's hard to call the shares undervalued.
I own HQL and THQ. I did own HQH too for a while earlier this year, but rolled it up into the others. I also continue to own PRHSX and a few individual healthcare names.
Comments
"This is the first time an investigational drug for Alzheimer's disease has demonstrated a statistically significant reduction on amyloid plaque as well as a statistically significant slowing of clinical impairment in patients with prodromal or mild disease."
FYI:
Regards,
Ted
Major Fund Holders:
http://investors.morningstar.com/ownership/shareholders-major.html?t=BIIB
Concentrated Fund Holders;
http://investors.morningstar.com/ownership/shareholders-concentrated.html?t=BIIB®ion=usa&culture=en-US&ownerCountry=USA